Problems in the search for cognition enhancers.

Area of Science:

• Neuroscience
• Psychopharmacology
• Gerontology

Background:

• Cognitive-enhancing drugs could benefit patients with intellectual disabilities and dementia, groups largely overlooked by recent psychopharmacological advancements.
• The potential for cognitive enhancers to improve normal cognitive performance presents a broad therapeutic opportunity.

Purpose of the Study:

• To address the challenges in establishing suitable animal models for cognitive enhancer drug development.
• To explore the difficulties in clinical testing of cognitive enhancers, particularly concerning patient selection and data analysis.
• To propose new criteria for evaluating the efficacy of cognitive enhancers, focusing on quality of life.

Main Methods:

• Critique of current animal models, including lesion experiments and non-specific models (anoxia, vitamin deficiency).
• Emphasis on developing animal models that utilize learning paradigms relevant to patient-specific deficits.
• Discussion of clinical trial challenges, including patient selection, functional variability, and the need for novel statistical approaches.

Main Results:

• Current animal models are often inadequate, dictating drug types rather than reflecting clinical needs.
• Clinical trials face hurdles due to patient deterioration and inherent functional variability, complicating the assessment of drug efficacy.
• Existing measurement criteria may not adequately capture improvements in quality of life for patients and caregivers.

Conclusions:

• Despite significant challenges in model development and clinical testing, the pursuit of cognitive-enhancing drugs is crucial.
• Innovative animal models and statistical methods are needed to accurately evaluate drug efficacy.
• The ultimate goal should be to improve the quality of life for patients and their caretakers through successful cognitive enhancement therapies.